Registered South Africa · SAHPRA

SUPRELORIN 4,7 mg

Deslorelin Acetate

14/21.7/17 INN generic

What it does

Deslorelin is a medication that helps manage certain hormonal conditions.

Commonly used for: precocious puberty (early onset of puberty), hormone-dependent conditions

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
14/21.7/17
Registration date
2019/11/28
Expiry date
-
Status
Registered
Active ingredient
Deslorelin Acetate
Dosage form
-
Strength
-
Pack size
-
Therapeutic class
-
RxNorm RxCUI
1311744
Manufacturer / MAH
-
Applicant / LTR
Virbac RSA (Pty) Ltd
Country of origin
-

Source: South African Health Products Regulatory Authority · fetched 2026-04-15 21:26:29 · updated 2026-10-21 04:01:57

Disclaimer: This information is sourced from South African Health Products Regulatory Authority (South Africa). Always consult a qualified healthcare professional before using any medication.

About this medicine

Deslorelin is a medication that helps manage certain hormonal conditions.

What it treats

  • precocious puberty (early onset of puberty)
  • hormone-dependent conditions

How it works

Deslorelin works by reducing the production of certain hormones in the body.

Who it's for

This medication is for children and adults with specific hormonal issues.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: deslorelin

BNF-referenced

Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog, primarily used in veterinary medicine but also has applications in human medicine. It is utilized for its ability to suppress gonadal function, thereby reducing the levels of sex hormones such as testosterone and estradiol. Deslorelin is particularly noted for its role in the treatment of hormone-responsive conditions and for use in fertility treatments.

Indications

  • Prostate cancer
  • Endometriosis
  • Precocious puberty
  • Fertility treatments

Dosage

Children: Paediatric dosing must be obtained from the BNF for Children, as it varies based on the condition and patient age.

Adults: The adult dosage should be determined based on the specific condition being treated and is available in the BNF.

Mechanism of action

Deslorelin acts as an agonist of the GnRH receptor, leading to an initial stimulation of gonadotropin release from the pituitary gland. However, with continuous administration, it causes desensitization of the pituitary gland, resulting in decreased secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which subsequently lowers the production of sex hormones from the gonads.

Pharmacodynamics

By modulating the release of gonadotropins, deslorelin effectively reduces the levels of circulating sex steroids. This action is particularly useful in managing hormone-sensitive conditions such as prostate cancer, endometriosis, and precocious puberty. The reduction in hormone levels can help alleviate symptoms associated with these conditions.

Pharmacokinetics

Deslorelin is administered via subcutaneous or intramuscular injection. It has a relatively long half-life due to its stability as a GnRH analog, allowing for prolonged action compared to natural GnRH. Metabolism primarily occurs through enzymatic degradation, and excretion is mainly via the urine. The pharmacokinetic profile can be influenced by factors such as the route of administration and individual patient characteristics.

Adverse effects

  • Injection site reactions
  • Headache
  • Nausea
  • Vasodilation
  • Hot flushes

Precautions

  • Monitor for signs of hypersensitivity
  • Use caution in patients with cardiovascular disease
  • Evaluate for potential endocrine disorders

Pregnancy

Deslorelin should not be used during pregnancy as it may affect fetal development.

Breast-feeding

Use with caution in breastfeeding women; effects on milk production are unknown.

Storage

Store at 2 to 8 degrees Celsius. Protect from light.

Formulations

  • Implant 4.7 mg
  • Injectable solution 0.5 mg/mL
PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: deslorelin

PubChem CID 25077495

Molecular formula: C64H83N17O12

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.